Ernexa Therapeutics (ERNAW) Retained Earnings (2010 - 2026)

Ernexa Therapeutics has reported Retained Earnings for 17 years, with the latest figure at -$251.1 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 4.76% year-over-year to -$251.1 million; the trailing twelve-month figure through Mar 2026 stood at -$251.1 million (down 4.76% YoY), and the FY2025 full-year result was -$245.6 million, down 6.09% from the prior year.
• Retained Earnings for Q1 2026 stood at -$251.1 million, down from -$245.6 million in the prior quarter.
• The five-year high for Retained Earnings was -$150.1 million in Q1 2022, with the low at -$251.1 million in Q1 2026.
• Historically, Retained Earnings has averaged -$201.0 million across 5 years, with a median of -$193.6 million in 2024.
• Annual changes were most pronounced in 2022 — Retained Earnings slumped 309.34% — and 2026, when it decreased 4.76%.
• Ernexa Therapeutics' Retained Earnings stood at -$165.3 million in 2022, then slipped by 13.12% to -$187.0 million in 2023, then dropped by 23.83% to -$231.5 million in 2024, then decreased by 6.09% to -$245.6 million in 2025, then decreased by 2.24% to -$251.1 million in 2026.
• The last three Retained Earnings figures came in at -$251.1 million (Q1 2026), -$245.6 million (Q4 2025), and -$244.1 million (Q3 2025), per Business Quant data.